FDA oncology division director Harpreet Singh, M.D., has left the agency to join Precision for Medicine as chief medical ...

Long thought to be a target for a big M&A deal, Cytokinetics has taken a step towards going it alone for the ...

Days after AstraZeneca set out how new oncology drugs would help fuel its “bold” ambition to almost double its revenue by the ...

Takeda has taken a trip all the way to Shanghai to find just the right kind of glue to stick together a $1.2 billion biobucks ...

Tango Therapeutics has discarded one of its cancer drugs on the dancefloor after the USP1 inhibitor was linked to reports of ...

Palisade Bio’s PDE4 inhibitor to treat the inflammatory bowel disease ulcerative colitis appears to be effective in mice, ...

Roche and the government of Abu Dhabi have set up a new public-private partnership to study spinal muscular atrophy and ...

A head-to-head study from Medtronic showed that its minimally invasive approach to reaching tissues in the lung suspected of harboring cancer could be just as effective as the current standard of care ...

Cue Health is taking last week’s FDA warning letter—and the agency’s public missive urging users to throw its central product ...

A digital pathology collaboration between Microsoft, the University of Washington and Providence health network aims to ...

Biogen is placing a $1.15 billion bet on Chris Viehbacher’s diversification vision. The upfront payment has secured Biogen a ...

A month after Evotec first alluded to a “strategic reset” to rebalance the company, the German biotech has revealed the end ...